| 1 |
33585999 | Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. | 2021 May |
2 |
| 2 |
34169393 | Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. | 2021 Aug |
2 |
| 3 |
31681603 | Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs. | 2019 |
1 |
| 4 |
29436642 | Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells. | 2018 Apr |
2 |
| 5 |
29675680 | A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation. | 2018 Aug |
2 |